Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LYB017
- Development stage
- Phase 1
- Lead developer
- Patronus Biotech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
LYB017 is an investigational recombinant malaria vaccine developed by Patronus Biotech. It is designed using the company's proprietary Universal Virus-Like Particle (U-VLP®) technology platform, which presents antigens in a highly immunogenic particulate format to elicit robust humoral and cellular immune responses. LYB017 is formulated with the A02B adjuvant, a synthetic saponin-based adjuvant system containing QS-21 and monophosphoryl lipid A (MPL) designed to enhance vaccine efficacy. The vaccine is currently being evaluated in a Phase I clinical trial to assess its safety, tolerability, and immunogenicity in healthy adults.
Beyond the preview
Go deeper on LYB017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LYB017.